Plague - Pipeline Review, H1 2017

Published: Feb, 2017 | Pages: 87 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Plague - Pipeline Review, H1 2017, provides an overview of the Plague (Infectious Disease) pipeline landscape.

Plague is an infection caused by the bacterium Yersinia pestis. The organism is transmitted to humans who are bitten by fleas that have fed on infected rodents or by humans handling infected animals. Symptoms include headache, fatigue or malaise, muscle aches, fever and chills, abdominal pain, diarrhea and vomiting, shock and bleeding from mouth, nose or rectum, or under skin. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Plague - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Plague (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Plague (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Plague and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical, Discovery and Unknown stages are 1, 14, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 3 and 1 molecules, respectively.

Plague (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Plague (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Plague (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Plague (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Plague (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Plague (Infectious Disease)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Plague (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Plague (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Plague - Overview
Plague - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Plague - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Plague - Companies Involved in Therapeutics Development
Achaogen Inc
Aradigm Corp
AvidBiotics Corp
Endacea Inc
GlaxoSmithKline Plc
Grifols SA
iBio Inc
Mucosis BV
Paratek Pharmaceuticals Inc
Prokarium Ltd
Syntiron LLC
Takeda Pharmaceutical Company Ltd
Tetraphase Pharmaceuticals Inc
Plague - Drug Profiles
(plague + small pox) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
anthrax + plague vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARD-3100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARD-3150 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BDM-I - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ciprofloxacin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gepotidacin mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GrePla - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISAS-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
L-971 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omadacycline tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
plague vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
plague vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
plague vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
plague vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
plague vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
plague vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
plague vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
plague vaccine 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
plazomicin sulfate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pneumonic plaque vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Pneumonic Plague - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Yoph Protein Tyrosine Phosphatase for Plague - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TP-271 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Yersinia pestis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Plague - Dormant Projects
Plague - Discontinued Products
Plague - Product Development Milestones
Featured News & Press Releases
Oct 18, 2016: Aradigm Announces Multi-million Dollar DTRA Funding for Inhaled Ciprofloxacins Formulations
Feb 14, 2013: BioDiem Extends Cooperative Agreement With USAMRIID
Nov 19, 2012: UK Scientists Report On Efficacy Of Aradigm's Lipoquin Against Pneumonic Plague
Jun 05, 2008: Computer Sciences Corporation's DynPort Vaccine Company To Continue Plague Vaccine Development
Nov 18, 2005: Computer Sciences Corporation's DynPort Vaccine Company Reaches Milestone In Plague Vaccine Clinical Trial
May 17, 2005: Wake Forest Scientists Find New Combination Vaccine Effective Against Plague
Jan 10, 2005: Computer Sciences Corporation's DynPort Vaccine Company Enters Clinical Trial For Plague Vaccine Candidate
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Plague, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Plague - Pipeline by Achaogen Inc, H1 2017
Plague - Pipeline by Aradigm Corp, H1 2017
Plague - Pipeline by AvidBiotics Corp, H1 2017
Plague - Pipeline by Endacea Inc, H1 2017
Plague - Pipeline by GlaxoSmithKline Plc, H1 2017
Plague - Pipeline by Grifols SA, H1 2017
Plague - Pipeline by iBio Inc, H1 2017
Plague - Pipeline by Mucosis BV, H1 2017
Plague - Pipeline by Paratek Pharmaceuticals Inc, H1 2017
Plague - Pipeline by Prokarium Ltd, H1 2017
Plague - Pipeline by Syntiron LLC, H1 2017
Plague - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
Plague - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2017
Plague - Dormant Projects, H1 2017
Plague - Discontinued Products, H1 2017